Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

One stock that might be an intriguing choice for investors right now is Denali Therapeutics Inc. DNLI. This is because this ...

Charles Schwab Investment Management Inc. grew its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) ...

In this article, we are going to take a look at where Denali Therapeutics Inc. (NASDAQ:DNLI) stands against the other companies Bezos is investing in. Since leaving his position as CEO of Amazon ...

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 33.8% in the fourth quarter, HoldingsChannel reports.

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today. The company’s ...

BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $28 from $30 and keeps a Buy rating on the shares. The firm updated for Q4 results, cash and share count and increased its ...

Denali Therapeutics Inc.’s DNLI share price has dipped by 10.43%, which has investors questioning if this is right time to buy.

Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug. Denali Therapeutics showcases ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

One stock that might be an intriguing choice for investors right now is Denali Therapeutics Inc. DNLI. This is because this security in the Medical - Biomedical and Genetics space is seeing solid ...